Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
| ▸ | PNMT | P11086 | 3/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.37 |
| ▸ | ABAT | P80404 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20182944 | 0.90 | GABRA1 (0.55) | GABRA1GABRB2PNMTDPP4LMNA | |
| SCHEMBL196227 | 0.87 | GABRA1 (0.57) | GABRA1GABRB2APOBEC3GLMNAPDCD1 | |
| SCHEMBL124524 | 0.80 | GABRA1 (0.50) | GABRA1GABRB2APOBEC3GLMNAHMGB1 | |
| SCHEMBL23486766 | 0.80 | GABRA1 (0.50) | GABRA1GABRB2APOBEC3GLMNAHMGB1 | |
| SCHEMBL366656 | 0.78 | ADAMTS4 (0.52) | GABRA1GABRB2PNMTLMNATAAR1 | |
| SCHEMBL2553273 | 0.77 | DPP4 (0.52) | PNMTDPP4APOBEC3GTAAR1PDCD1 | |
| SCHEMBL29437737 | 0.77 | DPP4 (0.52) | PNMTDPP4APOBEC3GTAAR1PDCD1 | |
| SCHEMBL11744835 | 0.76 | PNMT (0.43) | PNMTDPP4APOBEC3GTAAR1PDCD1 | |
| Hydrochloric Acid SCHEMBL1998632 | 0.76 | ADAMTS4 (0.50) | GABRA1GABRB2PNMTLMNATAAR1 | |
| SCHEMBL11648774 | 0.76 | GABRA1 (0.81) | GABRA1GABRB2APOBEC3GLMNAPDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112152-A1 | TRIPHENYLPHOSPHONIUM-TETHERED SALICYLAMINE DERIVATIVES | MTI BIOTECH, INC. | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112152-A1 | TRIPHENYLPHOSPHONIUM-TETHERED SALICYLAMINE DERIVATIVES | SHMT2, HSPA9, GOT2 | GABRA1 4084/4885GABRB2 3555/4885PNMT 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.